{"data":[{"accessionNo":"0002012383-26-003861","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":"92764N102","securityClass":"Common Stock","eventDate":"2026-09-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":20905681,"percentOfClass":12.4,"filedAt":"2026-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0000093751-26-000556","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001706431","issuerName":"VIR BIOTECHNOLOGY INC","ticker":"VIR","cusip":"92764N102","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":9964151,"percentOfClass":5.9,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0002100121-26-000992","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001706431","issuerName":"Vir Biotechnology Inc","ticker":"VIR","cusip":"92764N102","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Vanguard Portfolio Management","reportingCik":null,"personType":"IA","sharesOwned":11554377,"percentOfClass":6.85,"filedAt":"2026-07-31","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001493152-26-024001","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":"92764N102","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-31","reportingPerson":"SoftBank Vision Fund (AIV M1) L.P.","reportingCik":null,"personType":"PN","sharesOwned":10948093,"percentOfClass":6.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001493152-26-024001","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":"92764N102","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-31","reportingPerson":"SB Investment Advisers (UK) Limited","reportingCik":null,"personType":"CO","sharesOwned":10948093,"percentOfClass":6.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001493152-26-024001","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":"92764N102","securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-03-31","reportingPerson":"SVF Endurance (Cayman) Limited","reportingCik":null,"personType":"CO","sharesOwned":10948093,"percentOfClass":6.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0002100121-26-000797","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001706431","issuerName":"Vir Biotechnology Inc","ticker":"VIR","cusip":"92764N102","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Vanguard Portfolio Management","reportingCik":null,"personType":"IA","sharesOwned":9257235,"percentOfClass":5.79,"filedAt":"2026-04-29","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0000102909-26-002579","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001706431","issuerName":"Vir Biotechnology Inc","ticker":"VIR","cusip":"92764N102","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001012975-26-000222","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-02-27","reportingPerson":"Robert Nelsen","reportingCik":"0001219042","personType":"IN","sharesOwned":13534704,"percentOfClass":8.5,"filedAt":"2026-03-03","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001012975-26-000222","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-02-27","reportingPerson":"Keith Crandell","reportingCik":"0001219039","personType":"IN","sharesOwned":13189627,"percentOfClass":8.3,"filedAt":"2026-03-03","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001012975-26-000222","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-02-27","reportingPerson":"ARCH Venture Fund IX Overage, L.P.","reportingCik":"0001666307","personType":"PN","sharesOwned":12916663,"percentOfClass":8.1,"filedAt":"2026-03-03","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001012975-26-000222","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-02-27","reportingPerson":"ARCH Venture Fund IX, L.P.","reportingCik":"0001666306","personType":"PN","sharesOwned":12916663,"percentOfClass":8.1,"filedAt":"2026-03-03","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001012975-26-000222","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-02-27","reportingPerson":"ARCH Venture Partners IX, L.P.","reportingCik":"0001723173","personType":"PN","sharesOwned":12916663,"percentOfClass":8.1,"filedAt":"2026-03-03","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001012975-26-000222","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-02-27","reportingPerson":"ARCH Venture Partners IX Overage, L.P.","reportingCik":"0001723172","personType":"PN","sharesOwned":12916663,"percentOfClass":8.1,"filedAt":"2026-03-03","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001012975-26-000222","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-02-27","reportingPerson":"ARCH Venture Partners IX, LLC","reportingCik":"0001723174","personType":"OO","sharesOwned":12916663,"percentOfClass":8.1,"filedAt":"2026-03-03","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001012975-26-000222","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2026-02-27","reportingPerson":"Clinton Bybee","reportingCik":"0001219043","personType":"IN","sharesOwned":13008393,"percentOfClass":8.1,"filedAt":"2026-03-03","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001493152-26-007174","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-12-31","reportingPerson":"SB Investment Advisers (UK) Limited","reportingCik":null,"personType":"CO","sharesOwned":13116977,"percentOfClass":9.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001493152-26-007174","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-12-31","reportingPerson":"SoftBank Vision Fund (AIV M1) L.P.","reportingCik":null,"personType":"PN","sharesOwned":13116977,"percentOfClass":9.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vir"},{"accessionNo":"0001493152-26-007174","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001706431","issuerName":"Vir Biotechnology, Inc.","ticker":"VIR","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-12-31","reportingPerson":"SVF Endurance (Cayman) Limited","reportingCik":null,"personType":"CO","sharesOwned":13116977,"percentOfClass":9.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vir"}],"updatedAt":"2026-10-29T08:40:53.433Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/vir","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}